NCT02892123
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Includes any patient with HER2-expressing cancer that is either HER2 1+, 2+ or 3+ by immunohistochemistry (IHC)
Exclusions: Patients with untreated brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT02892123